

**REMARKS**

Claims 1-14 have been canceled without prejudice, claim 15 has been amended, and new claims 16-64 have been added. Claims 15-64 are now pending for the Examiner's consideration.

Claims 16-64 have been added to recite particular embodiments of the invention. The new claims are supported by claims 1-15 as originally filed, and no new matter is added.

Applicant respectfully requests favorable consideration of the pending claims.

**Objection to the claims**

Claims 10 and 15 were objected to for not following the proper formalities of providing the full names of abbreviations M-CSF and CSF1R. Claim 10 has been cancelled and claim 15 has been amended to incorporate the full name of the abbreviation CSF1R. Applicants have amended the claims as suggested by the Examiner, and respectfully request that the objections be withdrawn

**Allowable Subject Matter**

Claims 9, 11 and 12 were objected to as being dependent upon a rejected base claim but otherwise allowable if rewritten in independent form. Claims 9, 11 and 12 have been cancelled.

Claims 25, 45 and 55 now correspond to claims 9, 11 and 12, respectively, in their independent form and incorporate all of the limitation of the base claim and any intervening claims. Applicants have amended the claims as suggested by the Examiner and thank the Examiner for allowing these claims.

**Rejection under 35 USC § 112, first paragraph:**

Claims 1-8, 13 and 14 were rejected under 35 USC § 112, first paragraph, for the reasons set forth on pages 2-5 of the Office Action. The Examiner has rejected claims 1-8, 13 and 14 as allegedly failing to comply with the enablement requirement because of the phrase "excessive osteolysis". Claims 1-8, 13 and 14 have been canceled so this rejection is now moot. Accordingly, withdrawal of the rejection of claims 1-8 13 and 14 under 35 U.S.C. § 112, first paragraph is respectfully requested.

Applicant believes all claims are now in condition for allowance. Should there be any issues that have not been addressed to the Examiner's satisfaction. Applicant invites the Examiner to contact the undersigned attorney.

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time (for which Applicants hereby petition), please charge such fees to Deposit Account No. 16-1445.

Atty. Docket No. PC23581A  
Application No. 10/780,917

Respectfully submitted,

Date: March 16, 2007

/Reena R. Desai/

Reena R. Desai  
Agent For Applicants  
Registration No. 53,833

Pfizer Inc.  
Legal Division – Intellectual Property  
10555 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-3087  
Fax: (858) 678-8233